Uniqure N.V. (QURE)

$14.42 +0.46 (3.30%)
Market Cap 796.99M
Revenue (ttm) 27.12M
Net Income (ttm) -239.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -883.33%
Debt to Equity Ratio 1.53
Volume 903,465
Avg Vol 1,529,854
Day's Range N/A - N/A
Shares Out 54.78M
Stochastic %K 12%
Beta 0.08
Analysts Strong Sell
Price Target $35.09

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
Jadek6
Jadek6 Jul. 16 at 7:17 PM
$QURE Dog siht today ..5 years last month MATT KAPUSHIT blew up this company Still dog shit
0 · Reply
Tumble51
Tumble51 Jul. 15 at 11:59 PM
$QURE Classic Truth
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:12 PM
$QURE New Symbol for QURE was just authorized : $SSDD Same shit different day
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:08 PM
$QURE Where is the LEERINK support, hahahaha Oh ..that siht was jammed into dumb clients accounts LEERINK is onto another FAILED Biotech $HURA
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:07 PM
$QURE still hung up on accounts that copy the truth about QURE ...fcuk even this jade account knows Matt is a FCUK UP .hahaha …and says so Get over the truth before it is another $SAVA ..and $146 to $1.86 !!! Falling …. Oh Ive seen that posted here at $17 !! Guess what ..nothing changes @FundingMyBoat …not even your pathetic rants !! Matt still there ..a ZERO Revenues still don’t pay for manufacturing Losses continue Sounds like a POOR INVESTMENT Smarten up !!!! hahahaah $SAVA …..$SAVA ….$SAVA
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:01 PM
$QURE 🤣🤣🤣🤣😂
0 · Reply
FundingMyBoat
FundingMyBoat Jul. 15 at 4:01 PM
$QURE Why did you scrub your Wrangler4 account? Are you down to only 2 now? To fcking stupid to even change up your vernacular between accounts. Are you still keying Teslas dipshit?
0 · Reply
Dkll303
Dkll303 Jul. 15 at 2:58 PM
$QURE 🤣🤣😂😂🤣🤣😂😂. $13 once again Matt Kapushit once again..FAILS
0 · Reply
Rackbully17
Rackbully17 Jul. 15 at 2:41 PM
$QURE looking tasty
0 · Reply
Jadek6
Jadek6 Jul. 14 at 12:48 PM
$QURE @TheLocoPro ..get your posts in sync with @FundingMyBoat ….. See how that all works out , lol
0 · Reply
Latest News on QURE
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

Jun 11, 2025, 8:00 AM EDT - 5 weeks ago

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

Jun 2, 2025, 7:05 AM EDT - 6 weeks ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

May 28, 2025, 4:56 AM EDT - 7 weeks ago

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX CRBP

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025, 10:16 PM EDT - 2 months ago

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025, 7:05 AM EDT - 2 months ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

May 8, 2025, 5:16 AM EDT - 2 months ago

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 2 months ago

uniQure to Announce First Quarter 2025 Financial Results

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

Apr 21, 2025, 1:56 AM EDT - 3 months ago

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Apr 19, 2025, 8:31 AM EDT - 3 months ago

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

Apr 17, 2025, 10:27 AM EDT - 3 months ago

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

Apr 17, 2025, 7:17 AM EDT - 3 months ago

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

Feb 27, 2025, 7:05 AM EST - 4 months ago

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V.: A Potential Huntington's Play

Feb 26, 2025, 1:47 AM EST - 5 months ago

uniQure N.V.: A Potential Huntington's Play

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

Feb 20, 2025, 3:07 PM EST - 5 months ago

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Feb 7, 2025, 1:04 PM EST - 5 months ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Feb 7, 2025, 9:12 AM EST - 5 months ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Feb 3, 2025, 7:05 AM EST - 5 months ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Jan 30, 2025, 7:37 AM EST - 5 months ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

uniQure Announces Pricing of its Public Offering

Jan 8, 2025, 7:05 AM EST - 6 months ago

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

Jan 7, 2025, 4:49 PM EST - 6 months ago

uniQure Announces Proposed Public Offering

Final Trade: DVN, QURE, GOOGL, DFH

Dec 30, 2024, 6:31 PM EST - 7 months ago

Final Trade: DVN, QURE, GOOGL, DFH

GOOG GOOGL DFH DVN

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

Dec 10, 2024, 7:05 AM EST - 7 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Nov 21, 2024, 7:05 AM EST - 8 months ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:05 AM EST - 9 months ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

Oct 15, 2024, 7:05 AM EDT - 9 months ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

Sep 23, 2024, 7:05 AM EDT - 10 months ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Aug 15, 2024, 7:05 AM EDT - 11 months ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 6, 2024, 3:03 AM EDT - 1 year ago

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

Aug 1, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

Jul 23, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

What Led To A 150% Rise In UniQure Stock In A Week?

Jul 12, 2024, 8:00 AM EDT - 1 year ago

What Led To A 150% Rise In UniQure Stock In A Week?

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 9, 2024, 1:48 PM EDT - 1 year ago

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

Jul 9, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Jul 1, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Jul 1, 2024, 7:05 AM EDT - 1 year ago

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

Jun 3, 2024, 7:05 AM EDT - 1 year ago

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 7, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

Feb 28, 2024, 7:05 AM EST - 1 year ago

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure: The Valuation Got More Attractive

Feb 1, 2024, 2:25 PM EST - 1 year ago

uniQure: The Valuation Got More Attractive

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

Dec 19, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Dec 11, 2023, 7:30 PM EST - 1 year ago

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 8, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

Nov 29, 2023, 7:05 AM EST - 1 year ago

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 7, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CSL and uniQure Win 2023 Prix Galien USA Award

Oct 27, 2023, 10:00 AM EDT - 1 year ago

CSL and uniQure Win 2023 Prix Galien USA Award

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Oct 24, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

Oct 5, 2023, 8:18 AM EDT - 1 year ago

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

Gene therapy maker UniQure to cut about 20% of workforce

Oct 5, 2023, 7:21 AM EDT - 1 year ago

Gene therapy maker UniQure to cut about 20% of workforce

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

Oct 5, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

Jadek6
Jadek6 Jul. 16 at 7:17 PM
$QURE Dog siht today ..5 years last month MATT KAPUSHIT blew up this company Still dog shit
0 · Reply
Tumble51
Tumble51 Jul. 15 at 11:59 PM
$QURE Classic Truth
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:12 PM
$QURE New Symbol for QURE was just authorized : $SSDD Same shit different day
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:08 PM
$QURE Where is the LEERINK support, hahahaha Oh ..that siht was jammed into dumb clients accounts LEERINK is onto another FAILED Biotech $HURA
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:07 PM
$QURE still hung up on accounts that copy the truth about QURE ...fcuk even this jade account knows Matt is a FCUK UP .hahaha …and says so Get over the truth before it is another $SAVA ..and $146 to $1.86 !!! Falling …. Oh Ive seen that posted here at $17 !! Guess what ..nothing changes @FundingMyBoat …not even your pathetic rants !! Matt still there ..a ZERO Revenues still don’t pay for manufacturing Losses continue Sounds like a POOR INVESTMENT Smarten up !!!! hahahaah $SAVA …..$SAVA ….$SAVA
0 · Reply
Dkll303
Dkll303 Jul. 15 at 7:01 PM
$QURE 🤣🤣🤣🤣😂
0 · Reply
FundingMyBoat
FundingMyBoat Jul. 15 at 4:01 PM
$QURE Why did you scrub your Wrangler4 account? Are you down to only 2 now? To fcking stupid to even change up your vernacular between accounts. Are you still keying Teslas dipshit?
0 · Reply
Dkll303
Dkll303 Jul. 15 at 2:58 PM
$QURE 🤣🤣😂😂🤣🤣😂😂. $13 once again Matt Kapushit once again..FAILS
0 · Reply
Rackbully17
Rackbully17 Jul. 15 at 2:41 PM
$QURE looking tasty
0 · Reply
Jadek6
Jadek6 Jul. 14 at 12:48 PM
$QURE @TheLocoPro ..get your posts in sync with @FundingMyBoat ….. See how that all works out , lol
0 · Reply
Jadek6
Jadek6 Jul. 14 at 12:43 PM
$QURE ahhhh Matt Kapushit have you conned .. Ahhhh .. Still in the 13-teen bracket …ahhhh Delusional posts now ..sad story with you and thousands of others
0 · Reply
Tumble51
Tumble51 Jul. 13 at 5:39 PM
$QURE got that backwards like Matt Kapushit. Hard to make money with a LOSER CEO !! An out of work stock broker with a relative on the board Always works , lol..for them, NOT YOU
0 · Reply
TheLocoPro
TheLocoPro Jul. 13 at 12:31 PM
$QURE Get its rhythm going and trade its wide range as it moves up slow and steady. Hard to not make any $ here lol. 😂
0 · Reply
Jadek6
Jadek6 Jul. 13 at 12:14 PM
$CAPR $QURE $CAPR got a lesson in poor mgmt , and this board at QURE is complicit, keeping Matt ! Not a bad FDA, a BAD crew at both CAPR and QURE SRPT suffered the same , yet Doug is a seasoned Big Pharma guy , not a hack with the likes of these 2 CEO’s
0 · Reply
Jadek6
Jadek6 Jul. 13 at 12:10 PM
$QURE Sad sad pathetic pump .. It is all hype Closing plants Raising money A failure under Matt !
0 · Reply
Jadek6
Jadek6 Jul. 13 at 12:08 PM
$QURE. time for a refresher on QURE , after MATT pissed thru 2.5B and hired Leerink to do a secondary in November. 2024 to grab 400M more for his welfare checks at QURE. No science background, no ability to create value , and incompetent at negotiations. HIT IT, SAM !!🎵🎶🎵🎶🎹🎵🎹 Second verse same as the first ⬇️
0 · Reply
Jadek6
Jadek6 Jul. 13 at 11:59 AM
$QURE he started with CSL Behring , and they fcuked him up good It will come out Matt K is a relative of a Board Member Hahahaha
0 · Reply
Jadek6
Jadek6 Jul. 13 at 11:57 AM
$QURE …ahhhhhh still believing multiple accounts to defend this pos. This pos has been a pos since your boss Matt Kapushit fcuked up a deal with CSL Behring , manufacturing the Hema B drug and costing more to produce it than royalties pay QURE. Recent offering shows Matt went thru 2.5 B since 2020 , sold his options Your boy is on welfare there ..with a 13 dollar stock Merck, nor Pfizer , nor GSK, nor BMY will touch Matt, the ex stock broker , hahahaha … Keep up the poor work at QURE and options granted to you clowns there at 6.38 ..a huge win , hahahaha @FundingMyBoat …albu dabee Musharraf , hahaha Oh where is the money from the Lexington operation ? Pissed away , hahahah to support The MATT
1 · Reply
JFDI
JFDI Jul. 9 at 2:40 PM
who had the $QURE ?
1 · Reply
Dkll303
Dkll303 Jul. 9 at 2:29 PM
$QURE hahahah ...19 CENTS out of the Spark of Merck and a 10B purchase of Verona KAPUSTA blows another deal
0 · Reply
Rackbully17
Rackbully17 Jul. 8 at 4:34 PM
$QURE out +$735
0 · Reply
Rackbully17
Rackbully17 Jul. 8 at 3:18 PM
$QURE adding here
0 · Reply